Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT411 in Solid Tumors and ES-SCLC
NCT04101357Phase 2Terminated
- Sponsor
- BioNTech SE
- Start
- Jun 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of BNT411 in solid tumor, small cell lung cancer (SCLC), sponsored by BioNTech SE. Started Jun 2020; status: terminated.
02
Drugs
BNT411
03
Conditions
solid tumorsmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04101357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101357.